Find a Clinical Trial by Phase

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Back to Phases

Phase: III

46 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Asher, Arash	A011401	A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (IRB#45777)
Ayoub, Walid	GS-US-428-4194	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis
Burnison, Michele	A221505	A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (RT Charm) (IRB#54882)
Chung, Jeffrey	EP0092	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Padsevonil As Adjunctive Treatment Of Focal-Onset Seizures In Adult Subjects With Drug-Resistant Epilepsy
Darrah, Justin	A051301	A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed Oor Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype (IRB#557)
Daskivich, Timothy	56021927PCR3011	56021927PCR3011: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy (IRB#31)
Daskivich, Timothy	EA8143	EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (IRB#50240)
Faries, Mark	02-18	02-18: A Phase III, Multi-Centre Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (IRB#459)
Faries, Mark	20-214-29/CA045-022	20-214-29/CA045-022: A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) (IRB#865)
Faries, Mark	716-01	716-01: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716) (IRB#53866)
Faries, Mark	CA20976K	CA20976K : A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K) (IRB#308)
Figlin, Robert	17-214-09	17-214-09: A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma (IRB#57158)
Figlin, Robert	CA209-914	CA209-914: Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse (IRB#127)
Giuliano, Armando	AFT-25	AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial (IRB#48166)
Gupta, Amit	IIT2019-04-ROSSER-GH	IIT2019-04-ROSSER-GH: A Novel Multiplex ELISA Assay for Evaluating Patient with gross hematuria for bladder cancer (IRB#57056)
Gupta, Amit	IIT2019-05-ROSSER-MICROH	IIT2019-05-ROSSER-MICROH: A Novel Multiplex ELISA Assay for Evaluating Patients with Microscopic Hematuria for Bladder Cancer (IRB#57068)
Gupta, Amit	S1602	S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer (IRB#50035)
Gupta, Amit	S1806	S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (IRB#384)
Gutierrez, Rodolfo	R2810-ONC-1788	R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (IRB#57958)
Hage, Antoine	RIN-PH-304	A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Hamid, Omid	587-00	587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410)
Hamid, Omid	MK-7902-003	MK-7902-003: A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma(LEAP-003) (IRB#56450)
Hendifar, Andrew	EIIT-MENAC-2017-03	EIIT-MENAC-2017-03: A Randomised, Open-Label Trial Of a Multimodal Intervention (Exercise, Nutrition And Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent / Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (IRB#55738)
Huang, Edmund	VKTX01	A PIVOTAL PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS
Kamil, Elaine	021FSGS16010	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Lewis, Richard	ALXN1210-MG-306	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
Majlessipour, Fataneh	AALL1731	AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) (IRB#0140)
Majlessipour, Fataneh	AALL1732	AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (IRB#654)
Majlessipour, Fataneh	AAML1831	AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (IRB#952)
Majlessipour, Fataneh	AGCT1531	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (IRB#)
Majlessipour, Fataneh	ANBL1232	Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (IRB#40692)
Mandelbaum, Bert	SM04690-OA-10	A Phase 3, 28-Week, Multicenter, Randomized, DoubleBlind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
McArthur, Heather	BIG16-05/AFT-27/WO39391	BIG 16-05/AFT-27/WO39391: A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMPASSION030 AFT-27) (IRB#53409)
McArthur, Heather	MK3475-756	MK3475-756: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2 ) Breast Cancer (IRB#57046)
McArthur, Heather	POL6326-009	POL6326-009 (FORTRESS): An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer (IRB#49)
Melmed, Gil	M16-000	A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989
Melmed, Gil	M16-006	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease
Noureddin, Mazen	ARAMCHOL-018	A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH)
Noureddin, Mazen	MGL-3196-11	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Paquette, Ronald	S1803	S1803: Phase III Study Of Daratumumab/ /rHuPH20 (NSC- 810307) + Lenalidomide Or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (Mm) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) (IRB#755)
Patel, Jignesh	1245-0204	A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acUte heart faiLure (de novo or decompensatied chronic HF) who have been StabilisEd (EMPULSE)
Patel, Jignesh	ALN-TTR02-011	APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Patel, Jignesh	ION-682884-CS2	A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Rader, Florian	CR0002	A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension
Wentzel, Kristopher	8951-CL-0301	8951-CL-0301: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (IRB#53519)
Zumsteg, Zachary	GTI-4419-301	GTI-4419-301 (ROMAN): Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (IRB#370)